Top Breaking News | More News | Featured Stories | News By Subject | Event News | Investor News | News Archive | Search News
Get Our FREE
Industry eNewsletter
email:    

Investor News

Clinical Development News
Pre-Clinical
IND
Phase I - Safety
Phase II - Safety and Efficacy
Phase III - Controlled Safety and Efficacy
BLA/NDA/ANDA
PDUFA
Approvable Letters
Approval and Marketing Clearance
Post-Approval
Discontinued
Recalls and Warnings

Deals & Dollars News
Alliances
Earnings Reports
Financial
Investor
Mergers and Acquisitions
Start-Ups

IPO News
IPO


Clinical - Post-Approval (Research/Post Marketing/Phase IV)
Roche (RHHBY) Suffers A Double Blow As Breast Cancer, Alzheimer’s Drug Studies Fail; Pulls Plug On ALZ's Drug Development 12/19/2014 6:02:39 AM
Genentech (RHHBY) Provides Update On Phase 3 MARIANNE Study In People With Previously Untreated Advanced HER2-Positive Breast Cancer 12/19/2014 6:09:33 AM
FDA Breakthrough Status For Genentech (RHHBY)'s Lucentis 12/16/2014 6:33:51 AM
Pfizer (PFE)'s Top Selling Drug Doesn't Help Patients With Lower Back Pain 12/11/2014 6:08:24 AM
Merck & Co. (MRK)'s Keytruda Shrank Tumors In Hard-To-Treat Breast Cancer Patients 12/10/2014 7:34:24 AM
Hemispherx Biopharma (HEB) Announces Data Showing Inhibition Of Ebola By Ampligen® Enlarged By Howard University Research 12/9/2014 10:47:49 AM
Amgen (AMGN)'s Kyprolis Delivers In Phase 3 Multiple Myeloma Study 12/8/2014 6:10:35 AM
Gilead Sciences, Inc. (GILD) Presents Follow-Up Data From Zydelig Registrational Studies In Patients With Chronic Lymphocytic Leukemia, Follicular Lymphoma And Small Lymphocytic Lymphoma 12/8/2014 10:36:47 AM
Amgen (AMGN) And Onyx Pharmaceuticals, Inc. (ONXX) Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 12/8/2014 6:12:14 AM
EXCLUSIVE: NHS Uses Ineffective IPF Therapy 12/5/2014 7:00:07 AM
National Institute for Clinical Excellence (NICE) Requests More Info On Novartis AG (NVS)'s Xolair To Treat Chronic Hives 11/19/2014 6:18:36 AM
Merck & Co. (MRK)'s Vytorin Proves Effective; IMPROVE-IT Trial Achieves Primary Endpoint 11/17/2014 12:45:21 PM
Esperion Therapeutics, Inc. (ESPR) Climbs As CEO Lauds Merck & Co. (MRK)'s Zetia Data 11/19/2014 8:33:03 AM
Alexion Pharmaceuticals Inc. (ALXN) Release: Longer-term Outcome Data From The Largest Prospective Trial Of Soliris® (Eculizumab) In aHUS Underscore The Effectiveness Of Ongoing Soliris Treatment 11/17/2014 12:02:27 PM
Confident Merck & Co. (MRK) Expects No Writedowns For Zetia, Vytorin Cholesterol Drugs 11/11/2014 5:54:44 AM
1234567
//-->